Outsourcing solid dose manufacturing trends

The pharmaceutical industry is under immense pressure to reduce timelines and any associated costs when it comes to oral solid dosage (OSD) drug development and manufacturing. Many drug developers are choosing to unload some of this responsibility by outsourcing to contract development and manufacturing organisations (CDMOs).

Today, drug development companies face several challenges that are having an impact on oral solid dose drug development and manufacturing.

Providers that have the ability to work on a project from early development through to commercial manufacturing are able to gain a solid understanding of the oral solid dose product being developed and are well equipped to handle any issues that may arise during a project.

Today, drug development companies face several challenges that are having an impact on oral solid dose drug development and manufacturing. Most notable is the complex nature of new molecules that are frequently affected by difficulties related to their bioavailability, formulation, stability, manufacturability, and scalability.

As these increasingly complex compounds continue to drive demand for more diverse technical requirements and supply chain needs, outsourcing is becoming a crucial component in ensuring these products reach commercial manufacture in the most efficient way possible. 

Click here to read more from Recipharm’s Vice President of Manufacturing Services, Erik Haeffler.